Brean Capital Comments on Ohr Pharmaceutical (OHRP) Phase 2 wet AMD Data
Get Alerts OHRP Hot Sheet
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Brean Capital analyst Jonathan Aschoff commented on Ohr Pharmaceutical (NASDAQ: OHRP) top-line final Phase 2 wet AMD results, saying they compare better to interim data than it may seem.
Aschoff explained, "Ohr announced its top-line final Phase 2 wet AMD results, and most importantly, marked benefit in vision gains of ≥3 lines and mean visual acuity was demonstrated in the patient subset having classic containing CNV, with less benefit observed in the overall population. We note that a key data analysis difference between the final dataset and the interim dataset is that final data used an ITT population LOCF analysis, versus the more forgiving completers analysis used at interim. The completers analysis at interim was prespecified, and at final it was to include multiple populations, yet Ohr chose only the most conservative analysis."
"At final, a clear statistical trend was seen in the ≥3 line responder endpoint, which has already been selected for Phase 3 after Ohr's EOP2 meeting with the FDA, despite no statistical significance on any efficacy endpoint, but we contend that a Phase 3 trial with about 150 patients per arm should be sufficient for adequate powering. Furthermore, in classic CNV containing patients, Ohr's 42% versus 28% ≥3 line responder analysis still numerically beats Ophthotech's 39% versus 32%. Given Phase 2 enrollment criteria differences, we view OHR-102 as at least as good as Fovista and note the enormous valuation differential. Detailed Phase 2 results will be at ARVO in early May. To allow for Ohr to fully analyze Phase 2 and determine optimal Phase 3 entry criteria, we project Phase 3 initiation in 2H15, a 3-6 month delay from the originally anticipated 2Q15 start," added the analyst.
For an analyst ratings summary and ratings history on Ohr Pharmaceutical click here. For more ratings news on Ohr Pharmaceutical click here.
Shares of Ohr Pharmaceutical closed at $8.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teleperformance (TEP:FP) (TLPFY) PT Lowered to EUR125 at RBC Capital, 'perceived risk profile makes it a no-fly zone for many investors'
- Monness, Crespi, Hardt Downgrades Palantir Technologies Inc. (PLTR) to Sell on 'egregiously rich valuation... darkest days of this economic downturn are ahead of us'
- Home Depot (HD) PT Raised to $360 at Telsey, 'in the long term, Home Depot should remain a winner in retail'
Create E-mail Alert Related Categories
Analyst Comments, Hot Comments, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!